# Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions

> **NCT05497063** · PHASE1 · UNKNOWN · sponsor: **Emzor Pharmaceutical Industries Limited** · enrollment: 70 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine
- **DRUG:** G-COSPE® tablets

## Key facts

- **NCT ID:** NCT05497063
- **Lead sponsor:** Emzor Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05497063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05497063, "Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05497063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*